Researchers have successfully tested a new type of coronavirus vaccine in humans for the first time, demonstrating that an entirely computer-designed vaccine candidate can be safe and trigger broad immune protection across multiple virus strains.
The trial involved 39 healthy volunteers aged 18 to 50 who received the experimental vaccine at clinical research facilities in Southampton and Cambridge. The vaccine produced no significant side effects, paving the way for larger, more diverse studies to confirm its effectiveness.
What sets this vaccine apart is its design strategy. Rather than targeting a single coronavirus strain like most existing vaccines, researchers used artificial intelligence and machine learning to analyze genetic data from coronaviruses worldwide. The AI identified common features shared across the entire Sarbecovirus family, which includes SARS-CoV-2, the original SARS virus, and bat coronaviruses that pose future spillover risks. The team then combined these shared characteristics into what they call a "super-antigen" that trains the immune system to recognize and fight multiple related viruses simultaneously.
The trial results, published in the Journal of Infection, showed the vaccine successfully stimulated immune responses against SARS-CoV-2, SARS, and related bat viruses that have never infected humans. This represents a fundamental shift in vaccine development philosophy.
"We've converted vaccine development from being reactive to being future proof," said Jonathan Heeney, a professor at Cambridge's Department of Veterinary Medicine who led the research. "Our vaccines will continue to provide protection against viruses even as they mutate into new strains."
The traditional vaccine model requires constant updating. Seasonal flu shots and revised COVID-19 vaccines are reformulated regularly because viruses evolve and existing vaccines become less effective against new variants. This AI-designed approach aims to break that cycle by anticipating how viruses will change and building protection against those future mutations in advance.
"We can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail," Heeney added.
The trial also marked a technological milestone. This was the first time a vaccine whose primary active ingredient was created entirely through computer simulations entered human testing. Researchers delivered the vaccine using a needle-free micro fluid jet system rather than traditional injection, offering a potential advantage for large-scale campaigns in challenging environments.
Animal studies preceding the human trial showed the vaccine generated strong immune responses against multiple coronaviruses, providing confidence in moving forward with clinical testing. Researchers now plan a larger Phase 2 study to evaluate immune responses in a broader, more diverse population and confirm the vaccine's range of protection.
The work was conducted by researchers at the University of Cambridge and DIOSynVax Ltd, a Cambridge spinout company founded in 2017 to develop digitally designed vaccines. The project received primary funding from Innovate UK.
Scientists emphasize the urgency of developing broader vaccine platforms. Influenza, coronaviruses, and Ebola viruses continue circulating in animal populations worldwide and are evolving constantly. The current vaccine system often fails to keep pace with these changes, leaving protection gaps when new variants or spillover events occur.
"If we can develop and clinically advance this new class of vaccines before a virus outbreak begins, millions of lives could be saved, lockdowns avoided and the economy preserved," said Saul Faust, chief investigator for the trial at the University of Southampton.
The same AI-powered design strategy could eventually be applied to other virus families, including Ebola viruses and influenza strains. DIOSynVax's pipeline already includes vaccine candidates targeting seasonal influenza, pandemic influenza threats, and hemorrhagic fever viruses, alongside additional coronavirus candidates.
While the trial results are encouraging, significant work remains. The vaccine still requires additional testing to confirm efficacy in real-world conditions and to demonstrate lasting protection. The Phase 2 trial will help determine whether the immune responses generated in this small group of healthy volunteers will translate to sustained protection across different populations and age groups.
Author Jessica Williams: "This is the kind of innovation that could fundamentally reshape how we respond to viral threats, but the proof will come in Phase 2 when we see if this works in people who actually represent the real world."
Comments